EP0446279A1 - Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon - Google Patents
Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferonInfo
- Publication number
- EP0446279A1 EP0446279A1 EP90900655A EP90900655A EP0446279A1 EP 0446279 A1 EP0446279 A1 EP 0446279A1 EP 90900655 A EP90900655 A EP 90900655A EP 90900655 A EP90900655 A EP 90900655A EP 0446279 A1 EP0446279 A1 EP 0446279A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- interferon
- squamous cell
- treatment
- cell carcinoma
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This invention relates to a method of treating squamous cell carcinoma with recombinant human alpha interferon by administering the interferon directly into the carcinoma lesion, i.e. intralesionally.
- Squamous cell carcinomas are cutaneous neoplasms found in humans and often arise in sun- damaged areas.
- Present treatment methods include various surgical techniques such as electrodesiccation and curettage, excision, cryosurgery and irradiation. Cure rates for the surgical techniques are generally quite good, however, non-surgical methods of therapy are generally thought to be more desirable.
- Interferons are a family of proteins which exhibit antiviral activity against certain viruses and anticancer activity against certain cancers. There are three types of interferons; alpha or leukocyte interferon, beta or fibroblast interferon and gamma or immune interferon.
- Human alpha interferon is a naturally occurring mixture of at least eleven components including those designated alpha-1 interferon and alpha-2 interferon. Human alpha interferon exhibiting biological properties similar to those of naturally occurring human leukocyte interferon can be made by recombinant methods.
- alpha interferon species or components are known and are usually designated by a numeral after the Greek letter alpha, and all are contemplated for use in this invention.
- human alpha-1 interferon and human alpha-2 interferon (sometimes called human alpha-2 interferon which includes human alpha-2a and human alpha-2b interferon; USAN: Interferon Alfa-2 including Interferon alfa-2a and Interferon Alfa-2b) are contemplated, with human alpha-2 interferon preferred.
- Interferon alfa-2 can be produced in bacteria using recombinant techniques as disclosed in Rubenstein, Biochem. Biophys. A ⁇ ta, 695, 5-16 (1982) .
- interferon alfa-2 may be prepared by recombinant-DNA methods disclosed by Nagata et al. , Nature, 284, 316-320 (1980), European Patent 32,134 and U.S. Patent 4,289,690.
- Various alpha-2-interferon species are disclosed in U.S. Patent 4,503,035.
- Preferred for use in this invention is the human interferon alfa-2b (hIFN- ⁇ 2b) .
- This invention relates to a method of treating squamous cell carcinoma with recombinant alpha interferon, preferably human recombinant DNA interferon alfa-2 (hIFN- ⁇ 2) , by administering intralesionally (by injection) to a patient in need of such treatment, a sufficient amount of human recombinant alpha interferon, preferably purified recombinant interferon alfa-2b, to be effective as an antitumor agent.
- recombinant alpha interferon preferably human recombinant DNA interferon alfa-2 (hIFN- ⁇ 2)
- alpha interferon means recombinant alpha-1 interferon and recombinant alpha-2 interferon (sometimes referred to as interferon alfa- 2) .
- interferon alfa-2 recombinant alpha-1 interferon and recombinant alpha-2 interferon
- this invention will be described in the following discussion using "human recombinant interferon alfa-2", “hIFN- ⁇ 2” or "hIFN- ⁇ 2b".
- liquid injectable pharmaceutically acceptable compositions are used.
- Such compositions can, for example, be prepared by diluting freeze dried hIFN- ⁇ 2 with sterile preservative free water to produce an isoto ⁇ ic solution containing the appropriate concentration of interferon.
- Other injectable compositions using saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension for injection can also be used.
- minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, preservatives, pH buffering agents arid the like, for example, sodium acetate or sorbitan monolaurate, can be incorporated into the compositions.
- hlFN- ⁇ 2 administered is critical only to the extent that it is effective for the therapeutic purpose.
- the quantity in the composition or formulation administered will, in any event, be an amount, effective to achieve an anti- squamous cell carcinoma effect in the subject being treated.
- the amount of hIFN- ⁇ 2 in a 0.15 ml. injectable dosage is about 1.5 x 10 6 I.U. (International Units) .
- the hIFN- ⁇ 2 is administered in doses of 1.5 x 10 6 I.U. three days a week for three weeks, i.e. 13.5 x 10 6 I.U. total.
- Treatments were conducted with freeze-dried human recombinant alpha-2 interferon which was in vials and was diluted with sterile water to produce an isotonic solution containing sufficient interferon concentration so that 0.15 ml of solution contained 1.5 x 10° International Units (IU) .
- Each lesion was injected with 0.15 ml of alpha-2 interferon using a 30- gauge needle. The needle was inserted into the lesion with care being taken to inject the entire amount intralesionally. The procedure was repeated for a total of three injections per week for three weeks. Thus, each lesion was injected with a total of 13.5 x 10 6 I.U.
- the entire treated area was excised eighteen weeks following completion of the treatment with alpha- 2 interferon.
- Clinical responses were measured during treatment and follow-up visits through evaluation of changes in lesion size and signs and symptoms at the site of the treated lesion.
- the excisional specimen was carefully evaluated histologically for the presence of any residual squamous cell cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27831588A | 1988-12-01 | 1988-12-01 | |
US278315 | 1988-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0446279A1 true EP0446279A1 (en) | 1991-09-18 |
Family
ID=23064525
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90900655A Pending EP0446279A1 (en) | 1988-12-01 | 1989-11-29 | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
EP89312404A Expired - Lifetime EP0372809B1 (en) | 1988-12-01 | 1989-11-29 | Medicament for the treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89312404A Expired - Lifetime EP0372809B1 (en) | 1988-12-01 | 1989-11-29 | Medicament for the treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0446279A1 (xx) |
JP (1) | JPH0647556B2 (xx) |
KR (1) | KR950011889B1 (xx) |
AT (1) | ATE92333T1 (xx) |
AU (1) | AU634511B2 (xx) |
CA (1) | CA2004202C (xx) |
DE (1) | DE68908119T2 (xx) |
DK (1) | DK103891D0 (xx) |
ES (1) | ES2058555T3 (xx) |
IE (1) | IE63121B1 (xx) |
IL (1) | IL92495A (xx) |
MY (1) | MY107071A (xx) |
WO (1) | WO1990006135A1 (xx) |
ZA (1) | ZA899113B (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9102512A (es) * | 1990-12-14 | 1992-06-01 | Schering Corp | Administracion oral de interferon alfa en el tratamiento de enfermedades del pulmon. |
IL100415A0 (en) * | 1990-12-21 | 1992-09-06 | Schering Corp | Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases |
EP0859630B1 (en) * | 1995-10-04 | 2002-12-11 | Schering Corporation | Combination of temozolomide and alpha-ifn for the treatment of advanced cancer |
US7294332B2 (en) | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
AU601741B2 (en) * | 1986-05-27 | 1990-09-20 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
-
1989
- 1989-11-29 ZA ZA899113A patent/ZA899113B/xx unknown
- 1989-11-29 AU AU48025/90A patent/AU634511B2/en not_active Ceased
- 1989-11-29 JP JP2501299A patent/JPH0647556B2/ja not_active Expired - Lifetime
- 1989-11-29 ES ES89312404T patent/ES2058555T3/es not_active Expired - Lifetime
- 1989-11-29 EP EP90900655A patent/EP0446279A1/en active Pending
- 1989-11-29 KR KR1019900701665A patent/KR950011889B1/ko not_active IP Right Cessation
- 1989-11-29 DE DE89312404T patent/DE68908119T2/de not_active Expired - Fee Related
- 1989-11-29 AT AT89312404T patent/ATE92333T1/de not_active IP Right Cessation
- 1989-11-29 MY MYPI89001661A patent/MY107071A/en unknown
- 1989-11-29 IL IL9249589A patent/IL92495A/en not_active IP Right Cessation
- 1989-11-29 EP EP89312404A patent/EP0372809B1/en not_active Expired - Lifetime
- 1989-11-29 WO PCT/US1989/005287 patent/WO1990006135A1/en not_active Application Discontinuation
- 1989-11-29 CA CA002004202A patent/CA2004202C/en not_active Expired - Fee Related
- 1989-11-30 IE IE382889A patent/IE63121B1/en not_active IP Right Cessation
-
1991
- 1991-05-31 DK DK911038A patent/DK103891D0/da not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9006135A1 * |
Also Published As
Publication number | Publication date |
---|---|
DK103891A (da) | 1991-05-31 |
IE893828L (en) | 1990-06-01 |
KR900701311A (ko) | 1990-12-01 |
ZA899113B (en) | 1990-08-29 |
JPH0647556B2 (ja) | 1994-06-22 |
KR950011889B1 (ko) | 1995-10-12 |
WO1990006135A1 (en) | 1990-06-14 |
DE68908119D1 (de) | 1993-09-09 |
AU4802590A (en) | 1990-06-26 |
CA2004202A1 (en) | 1990-06-01 |
ES2058555T3 (es) | 1994-11-01 |
CA2004202C (en) | 2001-02-13 |
EP0372809B1 (en) | 1993-08-04 |
IE63121B1 (en) | 1995-03-22 |
JPH04500678A (ja) | 1992-02-06 |
ATE92333T1 (de) | 1993-08-15 |
MY107071A (en) | 1995-09-30 |
IL92495A0 (en) | 1990-08-31 |
DE68908119T2 (de) | 1993-11-18 |
EP0372809A1 (en) | 1990-06-13 |
DK103891D0 (da) | 1991-05-31 |
AU634511B2 (en) | 1993-02-25 |
IL92495A (en) | 1995-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5256410A (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
US5028422A (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
IE64765B1 (en) | Use of cytokines | |
Edwards et al. | Effect of intralesional a2-interferon on actinic keratoses | |
Harms et al. | A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-γ in the local treatment of cutaneous leishmaniasis | |
US5480640A (en) | Alpha interferon for treating prostate cancer | |
Bernard et al. | Transient focal neurologic deficits complicating interleukin‐2 therapy | |
US5002764A (en) | Treatment of actinic keratoses with alpha2 interferon | |
AU634511B2 (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
EP0225759B1 (en) | Interferon compositions | |
EP0248583B1 (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
Bleeker | Intralesional triamcinolone acetonide using the Port‐O‐Jet and needle injections in localized dermatoses | |
Doǧan et al. | Intralesional alfa-2a interferon therapy for basal cell carcinoma | |
Bartkowski-Dodds et al. | Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats | |
Ikić et al. | Interferon reduces recurrences of basal cell and squamous cell cancers | |
Streib | Distal ulnar neuropathy as a cause of finger tremor: a case report | |
Brody | Electrical Activity in Sympathetic Nerves of Immunologically Sympathectomized Rats. | |
Shiohara et al. | Interferon-γ as adjuvant therapy for resistant warts | |
Shuttleworth et al. | A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease | |
Lee et al. | Clinical trials of interferon-gamma in treating warts | |
Inui et al. | OK‐432 therapy for recalcitrant warts | |
Herxheimer | The action of drugs on the skin | |
Jackson | Treatment of superficial epitheliomatosis with an ointment containing demecolcin | |
Tsukuda et al. | Clinical efficacy of recombinant human granulocyte colony-stimulating factor in patients with head and neck cancer | |
Sparsa et al. | Skin Necrosis after Injection of PEG-Interferon a2b in an HCV-infected Patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 19910529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE |
|
XX | Miscellaneous (additional remarks) |
Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89312404.0/0372809 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 17.10.91. |